Anixa Biosciences Inc. announced that IP Australia granted it patent number 2020221280 for a composition-of-matter titled “Vaccine Adjuvants and Formulations.” The patent protects the company’s α‑lactalbumin‑based breast cancer vaccine through 2040 and adds to its existing portfolio in the United States, Europe, China, Japan and other markets.
The vaccine targets human α‑lactalbumin, a protein expressed in aggressive breast‑cancer subtypes such as triple‑negative disease. Clinical testing was conducted at the Cleveland Clinic under a Phase 1 protocol funded by the U.S. Department of Defense. The trial reported that the vaccine was safe, well‑tolerated and generated protocol‑defined immune responses in more than 74% of participants, meeting all primary endpoints.
Anixa holds an exclusive license to the underlying technology from the Cleveland Clinic, which will receive royalties and other commercialization revenues under the agreement. The company noted that no preventive breast‑cancer vaccine has yet received regulatory approval worldwide.
“This newly issued patent strengthens the global foundation we are building for our breast cancer vaccine,” said Dr. Amit Kumar, chairman and chief executive of Anixa Biosciences.
The development comes amid rising breast‑cancer incidence globally, with Australia reporting increasing case numbers despite high survival rates. Anixa’s patent filing underscores its strategy to expand intellectual‑property protection across key markets as it advances the vaccine toward later‑stage trials.
